Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

TUMOR RESISTANCE INDUCED BY SYNGENEIC BONE-MARROW TRANSPLANTATION AND ENHANCED BY INTERLEUKIN-2 - A MODEL FOR THE GRAFT VERSUS LEUKEMIA REACTION CANCER RESEARCH Kwak, L. W., Campbell, M. J., Levy, R. 1992; 52 (15): 4117-4120

Abstract

Lethally irradiated C3H/HeN mice reconstituted with normal syngeneic bone marrow survived significantly longer than unmanipulated control mice following challenge with a lethal dose of 38C13 lymphoma cells 2 to 3 weeks post-bone marrow transplantation (BMT). Although the magnitude of this effect was modest, it was highly reproducible. This resistance-producing effect of BMT could be enhanced by interleukin 2 administration and could be abrogated by anti-asialo-GM1 antiserum treatment of recipients. These findings are consistent with the hypothesis that cells with a natural killer phenotype are activated by BMT and can mediate tumor resistance. These studies provide a model to explore the cellular basis, independent of donor alloreactivity, of the graft antitumor effect of BMT observed in humans.

View details for Web of Science ID A1992JF74600009

View details for PubMedID 1638524